Medicine and Dentistry
Inflammatory Bowel Disease
100%
Biological Marker
43%
Crohn's Disease
37%
Patient with Inflammatory Bowel Disease
32%
Ulcerative Colitis
29%
Disease
29%
Patient with Crohn's Disease
23%
Gut Microbiome
21%
Disease Activity
20%
Infliximab
19%
Gut
19%
Vedolizumab
18%
Extracellular Matrix
17%
Collagen Type 4
15%
Tumor Necrosis Factor
15%
Treatment Response
12%
Collagen Type 1
12%
Genome Wide Association Study
11%
Collagen Degradation
11%
Disease Exacerbation
11%
Endoscopy
10%
Neutrophil
9%
Quality of Life
8%
Faecal Calprotectin
8%
Genetic Risk
8%
Gut Microbiota
8%
Liver Transplantation
7%
Thrombosis
7%
Patient with Ulcerative Colitis
7%
Proteomics
7%
Kidney Graft
7%
Leukocyte Elastase
7%
Biological Therapy
6%
Calgranulin
6%
C Reactive Protein
6%
Genetic Variability
6%
Irritable Bowel Syndrome
5%
Microbiome
5%
Combination Therapy
5%
Surgical History
5%
Biopsy
5%
Primary Sclerosing Cholangitis
5%
Mucosa
5%
Smoking
5%
Immunology and Microbiology
Inflammatory Bowel Disease
98%
Crohn's Disease
53%
Gut Microbiome
28%
Ulcerative Colitis
27%
Infliximab
18%
Vedolizumab
18%
Extracellular Matrix
17%
Microbiome
14%
Transplant Procedure
14%
Genome-Wide Association Study
13%
Epitope
13%
Neutrophil
12%
Immunoprecipitation
11%
Primary Sclerosing Cholangitis
11%
Coeliac Disease
10%
Collagen Degradation
10%
Genetic Variability
9%
Tumor Necrosis Factor
9%
RNA Sequence
8%
Single Nucleotide Polymorphism
8%
Antibody Blood Level
7%
Liver Transplantation
7%
Solid Organ Transplantation
7%
Genetic Variation
7%
Bacteriophage
7%
Gene Expression
7%
Enteritis
6%
Microflora
6%
Metagenomics
6%
Antibody Response
5%
Mucosa
5%
Colitis
5%
Inflammatory Disorder
5%
Intestine Flora
5%
C-Reactive Protein
5%
Whole Exome Sequencing
5%
Genetic Risk
5%
Biological Product
5%
Keyphrases
Inflammatory Bowel Disease
81%
Crohn's Disease
26%
Ulcerative Colitis
18%
Gut Microbiome
12%
Primary Sclerosing Cholangitis
9%
Type I Collagen
8%
Infliximab
8%
Disease Activity
8%
Biological Therapy
8%
Clinical Phenotype
7%
Disease Progression
7%
Induction Therapy
7%
Kidney Transplant Recipients
7%
Endoscopic Disease Activity
7%
Health-related Quality of Life
7%
Co-immunoprecipitation (co-IP)
7%
Antibody Epitope
7%
Host-microbe Interactions
7%
Genome-wide Association Study
6%
Fibrostenotic
6%
Fecal Calprotectin
5%
Collagen Degradation
5%
Vedolizumab
5%
TNF-α Antagonists
5%
Environmental Factors
5%
Treatment Response
5%
Inflammation
5%
Genetic Variants
5%
Type III Collagen
5%
Crohn's Colitis
5%
Gut Dysbiosis
5%
